Reactivation of BK virus in renal allografts causes a destructive chronic infection. This single-center retrospective cohort study describes the evolution of BK virus allograft nephropathy (BKVAN) from 63 kidneys (from 61 patients) using sequential histopathology (454 biopsies, averaging 7.8 AE 2.6 per kidney) followed for 60.1 mo. Uninfected protocol biopsies formulated time-matched control Banff scores (n = 975). Interstitial inflammation occurred in 73% at diagnosis, correlating with viral histopathology (r = 0.413, p = 0.008) and amplifying early injury with accelerated interstitial fibrosis and tubular atrophy (IF/TA, p = 0.017) by 3 mo. Prodromal simian virus 40 large T antigen (SV40T)-negative inflammation with viremia preceded the histological diagnosis in 23.8%. Persistent subacute injury from viral cytopathic effect was associated with acute tubular necrosis and ongoing interstitial inflammation, culminating in IF/ TA in 86.9%. Overall, cellular interstitial infiltration mitigated the intensity of subsequent tubular injury, SV40T, and tissue viral load, assessed by sequential paired histology (p < 0.001). Graft loss was predicted by high-level viremia (hazard ratio [HR] 4.996, 95% CI 2.19-11.396, p < 0.001), deceased donor (HR 3.201,, p = 0.026), and late acute rejection (HR 3.124, 95% CI 1.037-9.413, p = 0.043). Transplant failure occurred in 38.1%, with uncontrolled infection (58.3%) and SV40T-negative chronic rejection (41.7%) causing losses. BKVAN is characterized by subacute virus-induced tubular injury, inflammation, and progressive nephron destruction. Effective antiviral therapy remains an unmet clinical need.
Introduction
BK is a human polyomavirus of high prevalence and low morbidity, resulting in adult seroprevalence rates of 80-90%. After childhood infection via the respiratory route, BK virus establishes a lifelong subclinical infection within renal cortex and medulla (1) . When transmitted during kidney transplantation, virus can reactivate from injury or powerful immunosuppression (2, 3) . Early viral replication is common: Viruria and decoy cell shedding occur in 35-57% (2, 4) , peaking 2-6 mo after transplantation and mostly resolving. Viremia is found in 10-30%, and a smaller proportion of 1.1-10.3% progress to BK virus allograft nephropathy (BKVAN) (1) . Understanding the pathogenesis of BKVAN has changed clinical practice. Quantitative testing of BK viremia and viruria (5) and urinary cytology (6, 7) with introduction of preemptive screening programs can detect early infection. Reduced overall immunosuppression (8) and reconstitution of anti-BK virus cell-mediated immunity (9, 10) allows successful viral clearance and prevents destructive allograft infection (4, 8, (11) (12) (13) (14) .
Cross-sectional pathology studies describe BKVAN as tubulointerstitial nephritis associated with graft dysfunction (15) (16) (17) , and several classification systems are proposed. Longitudinal studies outline progression from latent infection to manifest disease (14, 16, 18) , histological changes paralleling viral load dynamics (18) and immunosuppression (13, 18, 19) , and late-resolving disease (18) . Extrinsic markers of viral replication generally follow progress in clinical practice; however, detailed descriptions of BKVAN using time-based histological scores of repeated pathology are lacking. noninfected histology, matched for time after transplantation. Study aims included evaluation of tissue viral loads and their relationship with viremia and histopathology at diagnosis, determination of the etiology and time course of inflammatory cells including from prodromal pathology, investigation of the pathophysiology of progressive tubular atrophy (TA) and interstitial fibrosis (IF), influence of viral clearance from tissue and blood on outcomes, and effects of late acute rejection, focusing on longitudinal histology.
Materials and Methods

Study population
The study group comprised all consecutive kidney and kidney-pancreas transplant recipients diagnosed with histologically proven BKVAN from 2002 to 2016 for whom accessible data were available. The institutional ethics approvals were HREC 2012/6/6.4(3563) and LNR/12/WMEAD/244 (amendment 1). Immunosuppression for standard-risk patients comprised basiliximab induction, tacrolimus, mycophenolate, and prednisolone.
Diagnosis and histological assessment of BKVAN
All cases of BKVAN were confirmed by pathology, characterized by intranuclear inclusions, typical smudgy nuclear chromatin, cellular atypia, and tubular epithelial cell degeneration, with rounding, detachment, and apoptosis (15) . BKVAN was categorized as diagnosis by inflammation and fibrosis using Drachenberg's description (15, 20) . Acute tubular necrosis signified tubular injury, cellular regeneration, or necrosis. Chronic T cell rejection was defined as persistent acute rejection in repeated biopsies in which virus was absent. Inflammation describes allograft cellular infiltration without implying causation. Polyomavirus tissue load was scored by cytopathic effect and simian virus 40 large T antigen (SV40T) immunohistochemistry using a three-tiered semiquantitative scale (≤1%, >1% to 10%, >10% tubules affected) (21) . Histological inflammation and nephron injury used Banff schema parameters (22) .
Histological normative ranges of individual Banff scores were formulated from uninfected protocol biopsies undertaken from May 2012 to July 2016. BKVAN and clinically significant viremia were excluded by negative pathology, SV40T immunohistochemistry, and contemporaneous BK DNA blood results (<1000 copies/mL or absent). These normative scores were compared against time-matched BKVAN scores for statistical inference. 3 -10 8 and 10 4 -10 10 copies/ mL, respectively, and assay limits were 898 and 450 copies/mL, respectively). Quantitative tests successfully complied with independent external quality assurance in molecular diagnostics (Quality Control for Molecular Diagnostics, http://www.qcmd.org). BK population genotypes were 1A/1C (16%), 1B (16%), II (16%), and type IV (5%) for prior sampling (n = 19).
Statistical analysis
The research design was a single-center, retrospective, cohort study of sequential histopathology describing the evolution of BKVAN. We used the unpaired Student t-test or Wilcoxon rank sum test for nominal data, a conditional binomial test for categorical data, Pearson and Spearman coefficients for correlations, logistic regression for dichotomous data, and Cox regression for survival data (univariate and multivariable adjusted models) and generalized estimating equations for repeated measurements. Multivariable models followed backward elimination. Graft loss was censored for patient death. Data are expressed as mean plus or minus standard deviation unless stated. The p-values were two-sided, and a probability <0.05 was considered significant.
Results
Study cohort and clinical information
The 63 BKVAN cases from 61 patients included two men whose first transplants failed from BKVAN and second grafts became reinfected (despite graft nephrectomy in one). The 53 kidney-and 10 kidney-pancreas recipients were followed for a median of 60. Normative control data From 1535 consecutive biopsies (screened 2012-2016), samples were excluded because of insufficient tissue (n = 23), past BKVAN (n = 73), current viremia (n = 167), active BKVAN (n = 8), and time mismatch (n = 263), leaving 975 protocol biopsies from 490 uninfected recipients (Table 1) . Control and BKVAN samples were taken 13.54 AE 23.4 and 13.49 AE 17.7 mo, respectively, after transplant (p-value not significant). Six normative subgroups were time-matched to the IQR of BKVAN biopsy times, corresponding to 0-3 mo (n = 531 biopsies) and 3-6 mo (n = 293) before diagnosis; at BKVAN diagnosis (n = 531); and 1-3 mo (n = 263), 4-12 mo (n = 250), and ≥12 mo (n = 77) after diagnosis.
The diagnosis of BKVAN and early inflammation BKVAN (n = 63) was verified by diagnostic pathology in all cases, 7 mo after transplant (median; IQR 3-12 mo, range 2-120 mo), with 76.2% occurring within 1 year. Biopsies for cause were indicated for dysfunction (n = 32, 50.8%), high viremia (>1 +04 copies/mL, n = 11, 17.5%), or both reasons (n = 2). Protocol screening discovered 22 (34.9%) unsuspected cases. Serum creatinine was 262 AE 213 lmol/L at BKVAN diagnosis compared with 125 AE 85 lmol/L for controls (p < 0.001) (Table S1 ). From 454 biopsy samples, an average of 7.8 AE 2.6 samples per kidney were available. The numbers remaining at 12, 24, and 36 mo from diagnosis were 259 biopsies (63 patients), 50 biopsies (31 patients), 25 biopsies (16 patients), and 13 biopsies (10 patients).
Interstitial inflammation occurred in 73.0% at diagnosis (i1 in 14, i2 in 21, i3 in 11) (Figures 1 and S1 Data are shown as mean AE SD or n (%). BKVAN, BK virus allograft nephropathy; NS, not significant.
unrelated to prior T cell or antibody-mediated rejection, HLA mismatch, regraft, or pretransplant DSA (all p-values not significant). Acute renal dysfunction with viremic inflammation occurred in 69.8%, treated by empirical pulse corticosteroids in 66.7%. Although early interstitial infiltration is consistent with an antiviral response, viral clearance from blood or tissue was unaltered (Table S2 ). At diagnosis, IF/TA was present in 34.9% and often mild, but 19.0% displayed moderate damage (Banff ct score = 2). TA scores at diagnosis correlated with posttransplant time (r = 0.42, p < 0.001) and renal function (log e serum creatinine, r = 0.31, p = 0.017) but not with inflammation, tubulitis, viral histology, SV40T, viremia, or ATN (all p-values not significant).
TA then steadily increased (Figures 1, 3 , and S1) and paralleled worsening chronic IF. Initial inflammation correlated with subsequent TA (r = 0.365, p = 0.008) and fibrosis (r = 0.354, p = 0.010) by sequential pathology (Figures 3 and S3 ). Banff i scores now correlated with TA (r = 0.310, p < 0.001) and fibrosis (r = 0.282, p < 0.001); and fibrosis correlated with TA (r = 0.892, p < 0.001). Development of severe TA (Banff ct score = 2) was predicted by baseline Banff i score (hazard ratio [HR] 1.557, 95% CI 1.083-2.237, p = 0.017) using univariate (Tables S2 and S3 ) and multivariable Cox regression (adjusted HR 1.552, 95% CI 1.019-2.273, p = 0.040) ( Figure 3 , Table S4 ). Mononuclear inflammation predicted subsequent TA (coefficient 0.211 AE 0.068, p = 0.002) and fibrosis (coefficient 0.200 AE 0.067, p = 0.003), using generalized estimating equations, independent of current or prior viral tissue loads. Mononuclear inflammation proportionally increased subsequent fibrosis (Tables S5 and S6 Figure 3 : Relationships between the extent of inflammation at BK virus allograft nephropathy (BKVAN) diagnosis with tubular atrophy and interstitial fibrosis 3-mo progress pathology (top left); inflammation with moderate severity tubular atrophy by actuarial survival (middle), and graft survival stratified by tubular atrophy grade at diagnosis (right top panels). Bottom panels illustrate the progression of chronic interstitial fibrosis according to inflammation at BKVAN diagnosis (left), persistent viremia (middle), and the occurrence of late acute rejection (right). *p < 0.05, **p < 0.01, ***p < 0.001.
Early inflammation and tubular injury Progressive chronic interstitial fibrosis by risk factors
We evaluated relative impacts of direct viral tubular injury versus indirect effects from inflammation and cause-andeffect interrelationships. Changes in TA and fibrosis scores (Dct and Dci) from sequential biopsy pairs (Figure 4) estimated the spot intensity of ongoing tubular injury. Positive D scores indicate active injury, zero is neutral, and negative scores denote healing. First biopsy pair interstitial mononuclear cells were followed by amelioration of tubular injury activity (linear regression coefficient Dct À0.143 AE 0.053, p = 0.008) (Figure 4) , implying benefit, compared without inflammation, which was associated with active tubular destruction-a "reversed" epidemiological relationship. Conversely, active tubular damage was followed by increased subsequent inflammation scores (coefficient Dct 0.238 AE 0.085, p = 0.006) (Figure 4) , suggesting some cellular response to injury. The presence of inflammatory cells was followed by regression of viral cytopathic effect and SV40T tissue load (p < 0.001) (Figure 4) . Dynamic changes in renal inflammation were briefly evaluated. The Banff Di scores positively correlated with tubular destruction (Dct, r = 0.294, p < 0.001) and fibrotic chronic healing (Dci score, r = 0.287, p < 0.001), indicating active tissue damage associated with expanding inflammatory cell populations.
BK virus clearance from blood and tissue Viral loads of 1635 AE 4060 9 10 3 copies/mL at diagnosis fell to 0.177 AE 0.409 9 10 3 by 3 mo (Figure 5 ). Sustained viral clearance was achieved in 33 kidneys, partial clearance (intermittent low-level viremia approximating 1 +03 copies/mL) was achieved in 12, and high-level viremia was uncontrolled in 18 (1 +04 copies/mL). SV40T scores decreased from 1.42 AE 0.66 at diagnosis to 0.80 AE 0.87 after 3 mo and to 0.55 AE 0.95 on final histology, including nephrectomy samples from failed allografts (n = 13). The median SV40T clearance time Univariate risk factors for graft loss included cytomegalovirus (CMV) serostatus, TA at diagnosis and 3-mo pathology, persistent viremia, and late acute rejection ( Table 2) . Multivariable Cox regression using parameters available at diagnosis found deceased donor, renal dysfunction, Banff ct score, and high CMV serostatus to be independent risk factors (model 1, Table 3 ). A comprehensive model using all factors found that deceased donor, late acute rejection, and persistent high-level BK viremia determined final outcome (model 2, Table 3 ). Figure 8 ) and the dominant driver of histological injury. The histological predictors of graft loss from the 3-mo progress biopsy included persistent SV40T, residual inflammation, chronic fibrosis, and TA ( episodes) during the subsequent period of low-dose maintenance immunosuppression and was diagnosed as acute T cell (n = 29), antibody-mediated (n = 2), or acute mixed rejection (n = 8). Late acute rejection episodes increased the risk of graft loss (HR 3.124, p = 0.043) (Table 3, Figure 8 ). Ten allografts failed from chronic cellular rejection (15.9%) in which virus was consistently absent from tissue and blood. Endarteritis occurred in four allografts (Banff v score = 1, n = 3; v score = 3, n = 1). Features of mixed antibody-mediated rejection were variably present in six kidneys, including C4d positivity (C4d score ≥2, n = 5) and/or microvascular inflammation (glomerulitis plus peritubular capillaritis score ≥2, n = 4). Mortality was 18% (11 of 61 patients) from 
Discussion
This longitudinal histological study outlines the evolution of BKVAN using sequential pathology. The most common presentation of established BKVAN was stage B (15, 20) disease, associated with infiltrating mononuclear cells and tubulitis. Stage A disease without inflammation was uncommon. Interestingly, some cases of "covert" SV40T-negative inflammation with viremia were later confirmed as BKVAN. The acute histological features of BKVAN-viral cytopathic effect, tubular cell necrosis, and cellular inflammation-often persisted and were gradually overlaid by increasing TA and chronic fibrosis, markers of nephron destruction. Similar studies describe ongoing virus-mediated tubular destruction and inflammation (14, 18, 19, 23) . Individual histological features were frequently coexpressed within a single biopsy sample, albeit with differing proportions according to disease stage and viral kinetics. Failed viral clearance resulted in destructive chronic infection, which culminated in allograft loss.
Interstitial inflammation occurred in 73% at diagnosis. It correlated with viremia and cytopathic pathology but not immune risk factors, consistent with an antiviral response. T lymphocyte-rich mononuclear cell infiltration is commonly observed in BKVAN (5, 15, 17, 24, 25) and correlates with tissue viral loads (23) . Following childhood infection, persisting subclinical virus within the genitourinary tract is suppressed by active immunity (1). Antigenspecific T cells can recognize nonstructural (small t and large T) antigenic targets (26, 27) and virus capsid proteins (VP1, VP2, and VP3) (27) (28) (29) . In early BK viremia, circulating CD4 + T helper and T cytotoxic cells (30) and specific polyfunctional CD8 + T cells (31) are detectable. Virus-specific lymphocyte clones infiltrate into infected kidneys, classified by next-generation sequencing of TCRs following ex vivo BK or allospecific HLA peptide stimulation (32) . These data suggest that early mononuclear infiltrating cells of BKVAN are responding to virus.
SV40T-negative inflammation with viremia also occurred in 22.8% of cases prior to subsequent pathological confirmation of BKVAN. Missed disease from sampling error (discordance rates between biopsy cores are 36.5%) (15) or T cell rejection indirectly stimulating viral reactivation (33) are potential explanations. Prodromal renal dysfunction (34) and an early inflammatory pattern of BKVAN masquerading as acute rejection (35) are both described. The cellular infiltrate of BKVAN closely resembles acute T cell rejection, with only minor differences in cell type (15, 23, 36) , protein (15, 25) , proteomic (37) , and gene expression profiles (38, 39) . We recommend screening for BK virus in tissue and blood when indication biopsy is undertaken (1); when presumptive rejection develops despite robust immunosuppression or during periods of peak viral reactivation (2-6 mo after transplant); or when excessive tubular necrosis, plasma cell, or neutrophil infiltration are present on histology (18, 23 ). An inadequate negative histological sample, accompanied by high-level viremia, should be managed by repeat diagnostic biopsy and reduced immunosuppression.
Following immunosuppression reduction, episodes of acute renal dysfunction characterized by inflammation (32, 40) . Early cellular interstitial inflammation in our study was followed by IF/TA (independent of viral load), consistent with immune-mediated damage amplifying the initial antiviral response. Although pulse methylprednisolone of inflammatory BKVAN often stabilized rising serum creatinine levels, progression of fibrosis and graft loss rates were unchanged. Other studies have described improved, stable, or deteriorating renal function following steroids (5, 19, 41, 42) . Because corticosteroids independently increase BK infection risk (5, 43) and enhance in vitro replication (44, 45) , we suggest use of their lowest effective dose and only when inflammatory BKVAN causes acute renal dysfunction, complemented by reduction of overall maintenance therapy to allow reconstitution of antiviral immunity (1, 4, 9, 13, 19) .
TA and chronic fibrosis accelerated from 3 mo after diagnosis, culminating in severe atrophy (Banff ct score = 3) in 85.7% of kidneys that failed from BKVAN. Progression to IF/TA was associated with persistent tubular cell injury, inflammation, and SV40T persistence on sequential histology ( Figure 5 ). Impaired graft survival and renal function are associated with IF/TA in other studies (14, 18) . Acute tubular cell necrosis was common, in 61.3% at diagnosis and 69.4% in established BKVAN and even appeared prior to diagnosis. Colocalization of cytopathic changes and SV40T within areas of TA indicate direct viral injury as the dominant mechanism of damage (23) . TA correlated with ATN prevalence, SV40T staining, and IF and progressively increased independently of interstitial cellular inflammation. Profibrotic genes are highly expressed in BKVAN (38) , and the observed chronic IF represents the pathophysiological response to injury. Inferior outcomes have been correlated with IF/TA at diagnosis or later (14, 15, 18, 41, 46) .
We hypothesize that replicating tubular epithelial cells are unable to repopulate lost cells within the hostile environment of an infected lumen, causing structural collapse with tubular obstruction and functional nephron failure. Reducing viral replication is essential to limit tubular attrition and allograft loss.
Graft failure occurred in 38.1% (44.5 mo after diagnosis), comparable to 46.2% averaged from multiple institutions (1) . Uncontrolled viral infection directly caused 58.3% of losses. At diagnosis, graft loss risk was predicted by TA, renal dysfunction, and deceased donor kidney: markers of reduced nephron reserve, as observed by others (14, 15, 23, 41, 46) . Although initial tissue and blood viral loads did not immediately affect outcome (14) , the subsequent ability to clear virus strongly determined graft survival; persistent SV40T in tissue and high-level viremia constituted adverse predictors, as reported previously (14, 18, 23, 27, 41) . Persistent high-level viremia was a powerful risk factor, increasing graft loss fivefold. Other studies have linked specific cellular responses to BK peptides (27, 47) and expansion of cytotoxic CD8 + T cells (31) or polyfunctional CD4 T cells (48) with viral control and outcome. A more effective antiviral cellular response may explain improved SV40T tissue-clearance rates and amelioration of the activity of tubular destruction when interstitial mononuclear cells were present. The concept of an ultimately beneficial mononuclear cell response in BKVAN is supported by other studies of antiviral inflammation (9, 10, 18, 19, 23, 31, 49) . The causal relationship between inflammatory cells and parenchymal tubular damage appeared to be bidirectional and complex. Although early antiviral inflammatory cells amplified short-term tubular injury, the continued presence of mononuclear cells correlated with viral clearance and reduced kinetics of tubular destruction over a longer time frame.
An important finding was the 41.7% of grafts lost to chronic rejection, which occurred following reduced immunosuppression and viral clearance. It affected 15.8% of BKVAN kidneys. T cell interstitial rejection was the most prevalent phenotype, endarteritis occurred in 40%, and antibody rejection markers (C4d and microvascular inflammation) variably occurred in 60%. Our late acute rejection rate of 61.9% exceeded 5-30% reported by others (4, (34) (35) (36) 50) , possibly explained by a longer and more complete follow-up (60.1 mo and 100%, respectively), lower diagnostic biopsy threshold, and more accurate causal assignment of allograft failure using histopathology. Late acute rejection increased graft failure risk threefold. Viruses powerfully stimulate adaptive and innate immunity, and transcripts of cytotoxic T cell, macrophage, and natural killer cells are increased in viremic or BKVAN blood (51) . Alloreactive TCR clonotypes that denote molecular rejection can appear in tissue after successful treatment (32, 40) . Our study found that substantial numbers of mononuclear cells persisted after sustained viral clearance in allografts that later failed from rejection. We recommended regular functional monitoring and prompt pathological diagnosis for episodes of acute renal dysfunction during periods of reduced immunosuppression. Following sustained viral eradication, modest strengthening of maintenance immunosuppression should be considered, especially for those patients at high immunological risk but regularly monitored for relapse of viremia.
The study strengths include large numbers of biopsyproven BKVAN cases with extensive sequential histopathology including prediagnosis protocol pathology, detailed and granular clinical data, and long-term followup. Normative control pathology from uninfected protocol biopsies allowed statistical inferences of Banff score abnormalities. STROBE guidelines for reporting cohort study were used (52). Our study, however, is single center. We deliberately excluded milder cases of "presumptive" BKVAN showing high-level viremia without demonstrable tissue virus, which have better outcomes. We quantified interstitial cells using accepted Banff i scores (22) , originally optimized for acute rejection classification, which specifically excludes inflammation within IF/TA (i-IF/TA score). Whether i-IF/TA or total inflammation scores are superior markers of viral inflammatory tubular destruction requires further research.
We conclude that the principal driver of the BKVAN phenotype is direct tubular injury by virus, with early acute antiviral responses amplifying injury, followed by chronic active tubulointerstitial inflammation. Acute lesions including acute tubular necrosis, viral cytopathic effect, and inflammation were accompanied by progressive and irreversible nephron destruction. Efficient viral clearance was improved by the presence of interstitial mononuclear cells, and failure to control infection determined graft loss. Late-rejection losses were also important. The current strategy of reduced immunosuppression to promote immune reconstitution and viral clearance while effectively managing patients with low-level screening viremia (2, 4, 8) remains suboptimal as applied to established BKVAN disease, with high failure rates, increased late rejection, and severe histological damage of surviving kidneys. An effective and nontoxic antiviral therapy remains an important unmet clinical need. Table S1 : Pathology results from full data set of BK virus allograft nephropathy biopsies (including before and after diagnosis) and protocol control histology. Data are shown as mean AE SD. *Time after transplant excludes implantation biopsy times. Table S2 : The effect of interstitial mononuclear cell inflammation at diagnosis on various sequelae. Univariate Cox regression for various selected outcomes using the Banff i score at BK virus allograft nephropathy diagnosis as a risk factor (the independent variable) that determines subsequent nephron damage by sequential histopathology, BK virus clearance from blood and tissue, and graft survival. 
